A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
Kestrel Therapeutics, Inc.
Kestrel Therapeutics, Inc.
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Montefiore Medical Center
National Cancer Institute (NCI)
Nammi Therapeutics Inc
National Cancer Institute (NCI)
Revolution Medicines, Inc.
Memorial Sloan Kettering Cancer Center
Conjupro Biotherapeutics, Inc.
Whitehawk Therapeutics, Inc.
City of Hope Medical Center
National Cancer Institute (NCI)
SystImmune Inc.
M.D. Anderson Cancer Center
Institut Paoli-Calmettes
Filamon LTD
Eli Lilly and Company
On Target Laboratories, LLC
PMV Pharmaceuticals, Inc
Mayo Clinic
Convalife (Shanghai) Co., Ltd.
University of California, Irvine
ViroMissile, Inc.
Sichuan Enray Pharmaceutical Sciences Company
A2 Biotherapeutics Inc.
Tizona Therapeutics, Inc
Essen Biotech
National Institutes of Health Clinical Center (CC)
Clasp Therapeutics, Inc.
New Phase Ltd.
Revolution Medicines, Inc.
University of Colorado, Denver
Institut Bergonié
Royal Marsden NHS Foundation Trust
SystImmune Inc.
Pheon Therapeutics
Daiichi Sankyo
Grey Wolf Therapeutics
Second Life Therapeutics
Eli Lilly and Company
Seagen Inc.
Medical College of Wisconsin
Varian, a Siemens Healthineers Company
Novartis
Mayo Clinic
Varian, a Siemens Healthineers Company
Seagen Inc.
RenJi Hospital
Degron Therapeutics Co.